Cti tracker

The Contraceptive Technology Innovation Tracker—CTI Tracker—houses information on potential contraceptive leads in early development, products in pre-clinical and clinical development, and products with single-country regulatory approval. The Tracker reports on both active development platforms and inactive R&D.

Contraceptive Pipeline Baseline Report ⬇ Export Database

For more information about contraceptive R&D, visit our partner databases

Show Filters
Active
Last updated: January 5, 2026
Cabotegravir Pellet Implant with Levonorgestrel

CAB + LNG Pellet

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Subdermal
  • Intended Duration: Short-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): CONRAD
Active
Last updated: January 5, 2026
BRDT Inhibitors

JQ1, NHWD870, CDD-1102

  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Not Yet Determined
  • Intended Duration: Not Yet Determined
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Cornell University, Baylor College of Medicine, Nantong University, Sichuan University, University of Minnesota
Active
Last updated: January 5, 2026
Annovera™

Nestorone + Ethinyl Estradiol One-Year Contraceptive Vaginal Ring, NES + EE Vaginal Ring

  • User: Female
  • Hormonal: Hormonal
  • Delivery Type: Vaginal Ring
  • Intended Duration: Long-Acting
  • Development Stage: Single-Country Approval
  • Developer(s)/Researcher(s): Population Council, NICHD, WHO, NIH, Gates Foundation, Avis and Clifford Barrus Medical Foundation, TherapeuticsMD
Active
Last updated: January 5, 2026
ADAM Vas-Occlusive Device

ADAM Air

  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Vas Deferens
  • Intended Duration: Long-Acting
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): Contraline, LLC
Active
Last updated: January 5, 2026
11b-MNTDC / 11β/19/17β

11b-methyl-19-nortestosterone 17b-dodecylcarbonate (11b-MNTDC)

  • User: Male
  • Hormonal: Hormonal
  • Delivery Type: Multiple
  • Intended Duration: Short-Acting
  • Development Stage: Phase I
  • Developer(s)/Researcher(s): BIOQUAL, Inc, NICHD, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, University of Washington, Health Decisions
Active
Last updated: November 21, 2025
VasDeBlock
  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Vas Deferens
  • Intended Duration: Long-Acting
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): VasDeBlock medical ApS
Active
Last updated: November 21, 2025
Tamsulosin

Flomax

  • User: Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Oral
  • Intended Duration: Pericoital
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Centro Universitario FMABC
Active
Last updated: November 21, 2025
SNAP Latex Condoms
  • User: Female/Male
  • Hormonal: Non-Hormonal
  • Delivery Type: Barrier
  • Intended Duration: Pericoital
  • Development Stage: Discovery & Early Development
  • Developer(s)/Researcher(s): University of Georgia
Active
Last updated: November 20, 2025
Polidocanol Foam
  • User: Female
  • Hormonal: Non-Hormonal
  • Delivery Type: Fallopian Tube
  • Intended Duration: Permanent
  • Development Stage: Pre-Clinical
  • Developer(s)/Researcher(s): Oregon Health & Science University